Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT05836025
PHASE2
Effect of Rapamycin in Ovarian Aging
Sponsor: Columbia University
View on ClinicalTrials.gov
Summary
The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways.
Key Details
Gender
FEMALE
Age Range
35 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-06-01
Completion Date
2026-09
Last Updated
2025-12-26
Healthy Volunteers
No
Conditions
Interventions
DRUG
Rapamycin
5mg/week of rapamycin orally for 12 weeks
OTHER
Placebo
5mg/week of placebo orally for 12 weeks
Locations (1)
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, United States